同型半胱氨酸对冠状动脉支架内再狭窄的影响Association between homocysteine and in-stent restenosis after coronary stenting
陈涵,王江友
摘要(Abstract)：
目的探讨同型半胱氨酸(homocysteine,HCY)对稳定型心绞痛(stable angina pectoris,SAP)患者支架内再狭窄的影响。方法 168例SAP患者成功行支架置入治疗,根据术后12~18个月冠状动脉造影结果分为再狭窄组(支架内狭窄≥50%,72例)及对照组(支架内狭窄<50%,96例);测定患者HCY水平,同时对支架置入前、置入后即刻及12~18个月后的冠状动脉造影结果进行计算机辅助的定量分析法(quantitative coronary analysis,QCA)评价。结果对照组HCY水平显著低于再狭窄组[(11.68±3.54)μmol/L比(18.54±4.39)μmol/L,P=0.012]。两组患者术前及术后即刻的最小管腔直径、狭窄程度比较,差异均无统计学意义(均P>0.05);术后12~18个月对照组狭窄程度显著低于再狭窄组[(33.24±12.52)%比(84.23±13.26)%,P=0.000];对照组的晚期管腔丢失显著小于再狭窄组[(0.36±0.21)mm比(1.82±0.68)mm,P=0.000]。多因素logistic回归分析显示,HCY与术后支架内再狭窄有关,回归系数为-0.578,P=0.023(OR 0.693,95%CI 0.548~0.952)。结论 HCY可能是SAP患者发生支架内再狭窄的原因之一。
关键词(KeyWords)： 稳定型心绞痛;支架内再狭窄;药物洗脱支架;同型半胱氨酸
基金项目(Foundation):
作者(Author): 陈涵,王江友
参考文献(References)：
- [1]Niccoli G,Montone RA,Ferrante G,et al.The evolving role of inflammatory biomarkers in risk assessment after stent implantation.J Am Coll Cardiol,2010,56(22):1783-1793.
- [2]Huang Y,Salu K,Wang L,et al.Use of a tacrolimus-eluting stent to inhibit neointimalhyperplasia in a porcine coronary model.J Invasive Cardiol,2005,17(3):142-148.
- [3]Tsai JC,Perrella MA,Yoshizumi M,et al.Promotion of vascular smooth muscle cell growth by homocysteine:a link to atherosclerosis.Proc Natl Acad Sci,1994,91(14):6369-6373.
- [4]莫合塔伯尔·莫敏,李建平,张岩,等.急性冠状动脉综合征患者血浆同型半胱氨酸水平与左心室射血分数及心功能严重程度的相关性研究.中国介入心脏病学杂志,2015,23(5):246-253.
- [5]中华医学会心血管病分会,中华心血管病杂志编辑委员会.经皮冠状动脉介入治疗指南(2009).中华心血管病杂志,2009,37(1):4-25.
- [6]Hu X,Wang Z,Wu H,et al.Ras ss DNA aptamer inhibits vascular smooth muscle cell proliferation and migration through MAPK and PI3K pathways.Int J Mol Med,2015,35(5):1355-1361.
- [7]Poddar R,Sivasubramanian N,Di Bello PM,et al.Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells:implications for vascular disease.Circulation,2001,103(22):2717-2723.
- [8]Majors A,Ehrhart LA,Pezacka EH.Homocysteine as a risk factor for vascular disease:enhanced collagen production and accumulation by smooth muscle cells.Arterioscler Thromb Vasc Biol,1997,17(10):2074-2081.
- [9]Mc Cully KS,Carvalho AC.Homocysteine thiolactone,Nhomocysteine thiolactonyl retinamide,and platelet aggregation.Res Commun Chem Pathol Pharmacol,1987,56(3):349-360.
- [10]Kosokabe T,Okumura K,Sone T,et al.Relation of a common methylenetetrahydrofolate reductase mutation and plasma homocysteine with intimal hyperplasia after coronary stenting.Circulation,2001,103(16):2048-2054.
- [11]Koch W,Ndrepepa G,Mehilli J,et al.Homocysteine status and polymorphisms of methylenetetrahydrofolate reductase are not associated with restenosis after stenting in coronary arteries.Arterioscler Thromb Vasc Biol,2003,23(12):2229-2234.
- [12]Genser D,Prachar H,Hauer R,et al.Relation of homocysteine,vitamin B(12),and folate to coronary in-stent restenosis.Am J Cardiol,2002,89(5):495-499.
- [13]Schnyder G,Roffi M,Flammer Y,et al.Association of plasma homocysteine with restenosis after percutaneous coronary angioplasty.Eur Heart J,2002,23(9):726-733.